CN101437515B - 烟碱、其类似物、其前体或其衍生物用于通过以预防形式或治疗形式参与的α-MSH改善治疗各种病理过程的应用 - Google Patents

烟碱、其类似物、其前体或其衍生物用于通过以预防形式或治疗形式参与的α-MSH改善治疗各种病理过程的应用 Download PDF

Info

Publication number
CN101437515B
CN101437515B CN200680054519.1A CN200680054519A CN101437515B CN 101437515 B CN101437515 B CN 101437515B CN 200680054519 A CN200680054519 A CN 200680054519A CN 101437515 B CN101437515 B CN 101437515B
Authority
CN
China
Prior art keywords
msh
alpha
nicotine
precursors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680054519.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN101437515A (zh
Inventor
阿图罗·索利斯埃雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101437515(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CN101437515A publication Critical patent/CN101437515A/zh
Application granted granted Critical
Publication of CN101437515B publication Critical patent/CN101437515B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN200680054519.1A 2006-05-08 2006-05-08 烟碱、其类似物、其前体或其衍生物用于通过以预防形式或治疗形式参与的α-MSH改善治疗各种病理过程的应用 Expired - Fee Related CN101437515B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2006/000031 WO2007129879A1 (es) 2006-05-08 2006-05-08 EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA.

Publications (2)

Publication Number Publication Date
CN101437515A CN101437515A (zh) 2009-05-20
CN101437515B true CN101437515B (zh) 2016-04-20

Family

ID=38667940

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680054519.1A Expired - Fee Related CN101437515B (zh) 2006-05-08 2006-05-08 烟碱、其类似物、其前体或其衍生物用于通过以预防形式或治疗形式参与的α-MSH改善治疗各种病理过程的应用

Country Status (13)

Country Link
US (4) US20090197921A1 (https=)
EP (4) EP2801359A3 (https=)
JP (1) JP2009536193A (https=)
KR (1) KR20130116374A (https=)
CN (1) CN101437515B (https=)
AU (1) AU2006343439B2 (https=)
BR (1) BRPI0621650A2 (https=)
CA (1) CA2651580C (https=)
DK (1) DK2801360T3 (https=)
ES (1) ES2683323T3 (https=)
MX (1) MX2008011473A (https=)
NZ (1) NZ572366A (https=)
WO (1) WO2007129879A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20110206642A1 (en) * 2009-10-15 2011-08-25 Cohava Gelber Preventing obesity-related metabolic syndrome with melagonesis
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
MX369060B (es) 2014-09-09 2019-10-28 Solis Herrera Arturo Métodos para tratar y prevenir enfermedades, trastornos, y condiciones oculares con melanina y análogos de melanina, precursores y derivados.
EP3442583B1 (en) 2016-04-12 2024-04-10 Arturo Solis Herrera Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
JP2007530586A (ja) * 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Effects of Nicotine on B-Endorphin ,aMSH and ACTH Secretion by Isolated Perfused Mouse Brains and Pituitary Glands ,in vitro;M.A.MARTY.V.G.ERWIN;《pharmacology Biochemistry and Behavior》;19851231;第22卷;317-325 *

Also Published As

Publication number Publication date
JP2009536193A (ja) 2009-10-08
DK2801360T3 (en) 2018-07-23
US20090197921A1 (en) 2009-08-06
CN101437515A (zh) 2009-05-20
EP2801358A2 (en) 2014-11-12
US20120270907A1 (en) 2012-10-25
MX2008011473A (es) 2008-09-24
EP2027860A1 (en) 2009-02-25
CA2651580A1 (en) 2007-11-15
AU2006343439A1 (en) 2007-11-15
EP2801360A3 (en) 2015-03-04
EP2801360B1 (en) 2018-04-25
EP2801359A3 (en) 2015-05-06
CA2651580C (en) 2016-01-19
BRPI0621650A2 (pt) 2011-12-20
EP2801359A2 (en) 2014-11-12
NZ572366A (en) 2012-02-24
US20160279116A1 (en) 2016-09-29
WO2007129879A1 (es) 2007-11-15
EP2801358A3 (en) 2015-03-04
EP2801360A2 (en) 2014-11-12
US20160008347A1 (en) 2016-01-14
AU2006343439B2 (en) 2013-05-16
KR20130116374A (ko) 2013-10-23
ES2683323T3 (es) 2018-09-26

Similar Documents

Publication Publication Date Title
US20160279116A1 (en) Therapeutic uses of nicotine
CN113248628B (zh) 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
CA2901410C (en) Use of levocetirizine and montelukast in the treatment of traumatic injury
US20130096048A1 (en) Treatment of sepsis and septic shock using ghrelin and growth hormone
CN117398372A (zh) Ostarine在抑制NLRP3炎症小体活化中的应用
ES2448837T3 (es) Agente que comprende G-CSF para la prevención y el tratamiento de neuropatía periférica diabética
JPH06510292A (ja) 慢性肝疾患治療剤
JP2021510157A (ja) 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
Pahuja et al. Successful Management of Hemodynamically Unstable Takotsubo Cardiomyopathy With Milrinone
CN108904782A (zh) Ctrp3用于制备预防治疗心肌肥厚药物的应用
RU2442584C2 (ru) ИСПОЛЬЗОВАНИЕ НИКОТИНА, ЕГО АНАЛОГОВ, ПРЕДШЕСТВЕННИКОВ И ПРОИЗВОДНЫХ ПРИ ЛЕЧЕНИИ РАЗЛИЧНЫХ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ, ПОДДАЮЩИХСЯ ЛЕЧЕНИЮ, ПУТЕМ ВВЕДЕНИЯ α-MSH ДЛЯ ПРОФИЛАКТИЧЕСКИХ ИЛИ ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ
JPH0655672B2 (ja) １−（３′，４′−ジエトキシベンジル）−６，７−ジエトキシ−３，４−ジヒドロイソキノリニウム−テオフイリン−７−アセテ−トからなる医薬組成物
CN108379557A (zh) 使用白介素因子-37治疗特发性肺纤维化
KR20090006069A (ko) 예방적 또는 치료적 형태로 투여된 α-ＭＳＨ를 사용하여 개선시킬 수 있는 다양한 병리 과정을 치료하기 위한 니코틴, 그의 유사체, 그의 전구체 또는 그의 유도체의 용도
WO2025256277A1 (zh) 黑素细胞刺激素α-MSH在治疗肝癌中的应用
HK40063175B (zh) 用於预防、改善或治疗纤维化的chp的用途
CN109125308A (zh) 秋水仙碱在预防和治疗缺血性脑血管疾病的新用途
Zi-Cong et al. Gastrointestinal Bleeding Associated With Nasojejunal Tube Injury in a Patient With Septic Shock: A Case Report
CN120860035A (zh) 牛磺鹅去氧胆酸在制备防治高血压药物中的应用
CN119907669A (zh) 用于治疗肝损伤的硝唑尼特
Hill The Inflammatory Response to Cardiopulmonary Bypass—Should It Be Treated?
Hayashi et al. Mistakes and Pitfalls of Brain Hypothermia Treatment
JPH07242565A (ja) 出血性ショック治療剤
WO2017181371A1 (zh) 贻贝粘蛋白产品及其抑制脏器炎症的应用
JP2010222289A (ja) 細胞死を予防するための医薬剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420